[en] Osteoporotic fractures are a major cause of morbidity in the population. Anti-resorptive agents have been, for more than 15 years, the mainstay of osteoporosis treatment worldwide. However, these medications provide only limited fracture reduction and may be linked to skeletal and non-skeletal long-term safety concerns. Therefore, some patients are considered candidates for bone-forming agents because they remain severely osteoporotic or because they failed antiresorptive therapy. Over the last decade, a particular interest was shown in the developmentofmedicationsabletoincreaseosteoblastsnumber,lifespan or activity, hence stimulating bone formation Peptides from the parathyroid hormone family and strontium ranelate were shown to significantly reduce fracture rates but strontium ranelate is no longer an option for treating osteoporosis because of its safety profile. New therapeutic options, including monoclonal antibodies against sclerostin seem to be promising but their role in the armamentarium of osteoporosis will depend on the results of the current phase 3 studies, assessing antifracture efficacy and long-term safety.
Disciplines :
General & internal medicine
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
NEUPREZ, Audrey ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Buckinx, Fanny ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Slomian, Justine ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique
Distèche, Stéphan ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Bone forming agents for the management of osteoporosis
Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Re-ginster JY on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.
Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.
Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011;4:593-604.
Rizzoli R, Reginster JY, Boonen S, Bréart G, Diez-Perez A, Felsen-berg D et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporis. Calcif Tissue Int 2011;89:91-104.
Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR et al.; IOF CSA Inadequate Responders Working Group. Osteoporos Int 2012;23:2769-74.
Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother 2011;12:2533-52.
Reginster JY, Taquet AN, Fraikin G, Gosset C, Zegels B. Parathyroid hormone in the treatment of involutional osteoporosis: back to the future. Osteoporos Int 1997;7:S163-7.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Min Res 2003;18:18-23.
Lindsay R, Scheels WH, Neer R, Pohl G, Adami S, Mautalen SC et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1-34)) in postmenopausal women with osteoporosis. Arch Int Med 2004;164:2024-30.
Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marci-nowska E et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-13.
Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA et al. Fracture Risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover. Bone 2006;39:237-43.
Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93.
Walsh JB, Lems WF, Karras D, Langdahl BL, Ljunggren O, Fah-rleitner-Pammer A et al. Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from die European Forsteo Observational 'Study (EFOS). Calcif Tissue Int. 2012;90:373-83.
Ljunggren O, Barrett A, Stoykov I, Landahl BL, Lems WF, Wlash JB et al. Effective osteoporosis treatement with teriparatide is associated witii enhanced quality of life in postmenopausal women with osteoporosis : the European Forsteo Observational Study. BMC Musculoskelet Disord 2013;14:251.
Graeff C, ChevalierY, Charlebois M, Varga P, Pahr D, Nickelsen TN et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 2009;24:1672-80.
Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009;24:726-36.
Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, Gonzalez de la Vera J et al.; EUROFORS Study Group. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 2011;22:1935-46.
MacDonald HM, Nishiyama KK, Hanley DA, Boyd SK. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int 2011;26:50-62.
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K et al. Effects of teriparatide versus alendronate for treating glucocor-ticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arth Rheum 2009;60:3346-55.
Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Ma-nolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:371-3.
Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zan-chetta JR et al. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Ann Intern Med 2007;146:326-39.
Shrader SP, Raggucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. Ann Pharmacother 2005;39:1511-6.
Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
Hansen S, Hauge EM, Jensen JE, Brixen K. Differing effects of PTH 1-34, PTH 1-84 and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis. An 18 month open-labeled observational study using HR-pQCT. J Bone Miner Res 2013;28:736-45.
Borgstrom F, Strom O, Marin F, Kutahov A, Ljunggren O. Cost effectiveness of teriparatide and PTH(l-84) in the treatment of postmenopausal osteoporosis. J Med Econ 2010;13:381-92.
Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fuku-naga M et al. Randomized teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012;97:3097-106.
Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M et al. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner Metab 2013 [Epub ahead of print].
Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T. Once-weekly infection of low-dose teriparatide (28.2 ug) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif Tissue Int 2013 [Epub ahead of print].
Cosman F, Lane NE, Bolognese MA, Zanchetta JR, Garcia-Her-nandez PA, Sees K et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010;95:151-8.
Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alex-andersen P et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(l-31)NH(2)] in Postmenopausal Women with Osteoporosis. Bone 2013;53:160-6.
Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Register JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-in-duced osteoporosis. J Clin Invest 1998;102:1627-33.
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000;15:944-51.
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-50.
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
Khosla S. Parathyroid hormone plus alendronate - A combination that does not add up. N Engl J Med 2003;349:1277-9.
Walker MD, Cusano NE, Sliney J Jr, Romano M, Zhang C, McMa-hon DJ et al. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 2012 [Epub ahead of print].
Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Har-didge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013;52:360-5.
Huang HT, Kang L, Huang PJ, Fu YC, Lin SY, Hsieh CH et al. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. Menopause 2012;19:1360-3.
Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 2012;23:2721-5.
Iwamoto J, Yago K, Sato Y, Matsumoto H. Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis. Clin Drug Investig 2012;32:547-53.
Narvaez J, Narvaez JA, Gomez-Vaquero C, Nolla JM. Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw. Osteoporos Int 2013;24:737.
EMA. Protelos: EPAR - Scientific Discussion. European Medicines Agency; 2005.
Reginster JY, Malaise O, Neuprez A, Bruyere O. Strontium ranelate in the prevention of osteoporotic fractures. Int J Clin Pract 2007;61:324-8.
Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 2011;22:1659-67.
Roschger P, Manjubala I, Zoeger N, Meirer F, Simon R, Li C et al. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. J Bone Miner Res 2010;25:891-900.
Doublier A, Farlay D, Jaurand X, Vera R, Boivin G. Effects of strontium on the quality of bone apatite crystals: a paired biopsy study in ostmenopausal osteoporotic women. Osteoporos Int 2013;24:1079-87.
Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women. Randomized comparison to alendronate. J Bone Miner Res 2013 [Epub ahead of print].
Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008;23:215-22.
Ma YL, Marin F, Stepan J, Ish-Shalom S, Moricke R, Hawkins F et al. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis. Bone 2011;48:972-8.
Jobke B, Burghardt AJ, Muche B, Hahn M, Semler J, Amling M et al. Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment. PLoS One 2011 [Epub ahead of print].
Busse B, Jobke B, Hahn M, Priemel M, Niecke M, Seitz S et al. Effects of strontium ranelate administration on bisphosphonate- altered hydroxyapatite: Matrix incorporation of strontium is accompanied by changes in mineralization and microstructure. Acta Biomater 2010;6:4513-21.
Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95.
Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.
Bruyere O, Collette J, Reginster JY. The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density. Osteoporos Int 2010;21:1039-40.
Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Al-banese C et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009;20:1663-73.
Reginster JY, Bruyere O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. Bone 2009;45:1059-64.
Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006;21:536-42.
Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008;67:1736-8.
Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women eighty years of age and older. J Bone Miner Res 2006;21:1113-20.
Bruyere O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 2010;21:1031-6.
Rizzoli R, Laroche M, Krieg MA, Frieling I, Thomas T, Delmas P et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 2010;30:1341-8.
Briot K, Benhamou CL, Roux C. Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry. J Clin Densitom 2012;15:176-85.
EMEA. Question and answers on the safety of Protelos/Osseor (strontium ranelate) 2007.
Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004:CD004526.
Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Postmarketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008;66:689-94.
Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010;21:1181-7.
Doublier A, Farlay D, Jaurand X, Vera R, Boivin G. Effects of strontium on the quality of bone apatite crystals: a paired biopsy study in postmenopausal osteoporotic women. Osteoporos Int 2013;24:1079-87.
Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010;21:723-32.
Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 2003;206:353-6.
Donneau AF, Reginster JY. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporos Int 2013 [Epub ahead of print].
Cooper C, Fox KM, Borer JS. Ischaemic cardiac events and use of strontium ranelate in postmonopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int 2013 [Epub ahead of print].
Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 2013 [Epub ahead of print].
Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McClos-key EV et al. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®. Osteoporos Int 2010;21:495-505.
Hiligsmann M, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010;46:440-6.
Hiligsmann M, Bruyere O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 2010;21:157-65.
Hiligsmann M, Ben Sedrine W, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporosis Int 2013;24:2291-300.
Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013;72:179-86.
Rossini M, Gatti D, Adami S. Involvement of WNT/|3-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int [Epub ahead of print].
Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785 : a potential treatment for osteoporosis. Expert Opin Biol Ther 2011;11:117-27.
LI X, Ominsky MS, Warmiington KS, Morony S, Gong J, Cao J et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strenth in a rat model of postmenopausal osteoporosis. J. Bone Miner Res 2009;24:578-88.
Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010;25:2647-56.
Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25:948-59.
Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strenght of nonfractured bones. J Bone Miner Res 2011;26:1012-21.
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014 [Epub ahead of print].